Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-26 · accession 0001683168-24-001216 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-26 | PHIO | Bitterman Robert J | Pres, CEO, Dir | P - Purchase | $0.91 | +2,500 | 19.0K | +15% | +$2,275 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2024-02-26 | P | A | 2,500 | $0.91 | 18,990 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. |